BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BIO-11006 Inhalation Solution: Phase IIa data

The double-blind, U.S. Phase IIa BREATH 1 trial in 172 patients with moderately severe COPD showed that twice-daily 75 mg BIO-11006 missed the primary endpoint of significantly improving FEV1 from baseline to day 21 vs. placebo (p=0.09). The twice-daily 75 mg dose also missed the secondary endpoint...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >